Literature DB >> 30129659

Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma.

Julien Dagher1,2,3, Brett Delahunt4, Nathalie Rioux-Leclercq2,3, Lars Egevad5, Geoff Coughlin6, Nigel Dunglison6, Troy Gianduzzo6, Boon Kua6, Greg Malone7, Ben Martin8, John Preston7, Morgan Pokorny6, Simon Wood7, Hemamali Samaratunga1,9.   

Abstract

AIMS: The aims of this study were to evaluate the impact of tumour-associated necrosis (TAN) on metastasis-free survival for clear cell renal cell carcinoma (RCC), and to determine whether TAN provides survival information additional to World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grading. METHODS AND
RESULTS: The study consisted of 376 cases of clear cell RCC treated by nephrectomy, for which follow-up was available. WHO/ISUP grade was assigned, and sections were assessed for the presence of TAN. American Joint Committee on Cancer (AJCC) pT staging category and tumour size were also recorded. The development of metastatic disease was taken as the clinical endpoint, and survival analyses, utilising univariate and multivariate models, were performed. WHO/ISUP grades were: grade 1, 35 cases (9.3%); grade 2, 188 cases (50.0%); grade 3, 91 cases (24.2%); and grade 4, 62 cases (16.5%). Staging categories were pT1-pT2 [234 tumours (62.2%)] and pT3-pT4 [139 tumours (37.0%)]. TAN was seen in 128 cases (34.0%). Neither TAN nor metastases were seen in grade 1 tumours. Among grade 2-4 tumours, those with TAN had a significantly worse prognosis than those without TAN (P = 0.017, P = 0.04, and P = 0.006, respectively). Multivariate analysis (WHO/ISUP grade, pT staging category, and TAN) showed all three variables to be independently associated with outcome (P = 0.009, P = 0.005, and P = 0.001, respectively). For all tumour grades and pT staging categories, it was found that the presence of TAN was associated with a 2.91-fold greater risk of metastatic disease.
CONCLUSION: Tumour-associated necrosis is an important prognostic factor for clear cell RCC, independently of WHO/ISUP grade. This supports the suggestion that TAN could be incorporated into tumour grading criteria.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  International Society of Urological Pathology; World Health Organisation; grading; prognosis; renal neoplasia; tumour necrosis

Mesh:

Year:  2018        PMID: 30129659     DOI: 10.1111/his.13737

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  The current status of renal cell carcinoma and prostate carcinoma grading.

Authors:  Brett Delahunt; Lars Egevad; John Yaxley; Hemamali Samaratunga
Journal:  Int Braz J Urol       Date:  2018 Nov-Dec       Impact factor: 1.541

2.  Clinical Significance of ADAMTS19, BMP7, SIM1, and SFRP1 Promoter Methylation in Renal Clear Cell Carcinoma.

Authors:  Raimonda Kubiliute; Algirdas Zalimas; Arnas Bakavicius; Albertas Ulys; Feliksas Jankevicius; Sonata Jarmalaite
Journal:  Onco Targets Ther       Date:  2021-10-05       Impact factor: 4.147

3.  Immunohistochemical Expression of CD44, MMP-2, MMP-9, and Ki-67 as the Prognostic Markers in Non-Clear Cell Renal Cell Carcinomas-A Prospective Cohort Study.

Authors:  Magdalena Chrabańska; Magdalena Rynkiewicz; Paweł Kiczmer; Bogna Drozdzowska
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

4.  Evaluation of the morphological features and unfavorable prognostic impact of dirty necrosis in renal cell carcinoma.

Authors:  Takashi Kuroe; Reiko Watanabe; Motohiro Kojima; Ryo Morisue; Masato Sugano; Takeshi Kuwata; Hitoshi Masuda; Shota Kusuhara; Nobuaki Matsubara; Shioto Oda; Tetsuo Ushiku; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-21       Impact factor: 4.553

5.  CT-Based Radiomics Signature for Preoperative Prediction of Coagulative Necrosis in Clear Cell Renal Cell Carcinoma.

Authors:  Kai Xu; Lin Liu; Wenhui Li; Xiaoqing Sun; Tongxu Shen; Feng Pan; Yuqing Jiang; Yan Guo; Lei Ding; Mengchao Zhang
Journal:  Korean J Radiol       Date:  2020-06       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.